Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Pulmatrix Inc. (NASDAQ:PULM)

Pulmatrix Inc. (NASDAQ:PULM)’s PUR1900 Awarded Designation

Pulmatrix Inc. (NASDAQ:PULM)

Shares of Pulmatrix Inc. (NASDAQ:PULM) fell 4.86% in Tuesday’s trading session to end the day at $1.76 a share. The sell-off comes just days after the U.S. Food and Drug Administration (FDA) designated the clinical stage biopharmaceutical company’s candidate drug, Pulmazole (PUR1900), as a Qualified Infectious Disease Product (QIDP).

Pulmatrix Inc. (NASDAQ:PULM)

FDA Designation

The designation is designed to speed up the development of novel drugs that have the potential to address important pathogens. Pulmatrix stands to enjoy up to 5 years of market exclusivity should the drug succeed in clinical trials and gain regulatory approval.

The candidate drug has already achieved orphan drug designation for the treatment of fungal infections in the airways of patients with cystic fibrosis. The QIDP designation further expands PUR 1900 status to include Asthma patients

“This second QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to severe asthma patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review and significantly expands the potential population we can treat with our Pulmazole product.

Patent Protection Milestone

In addition to FDA designation milestones, Pulmatrix Inc. (NASDAQ:PULM) has received two important patents from the United States Patent and Trademark Office (USPTO). One of the patents expands the potential of the company’s technology for delivering drugs directly to the lungs.

The company has developed a dry powder that it claims can fly easily through the airways and deliver a wide range of types of drugs. The technology is designed to increase the efficiency of drug delivery while also reducing the side effects associated with existing approaches.

The second patent expands the patent protection of Pulmatrix Inc. (NASDAQ:PULM) candidate drug PURO200 for the treatment of chronic obstructive pulmonary disease. The new patent broadens the intellectual property protection so that it is no longer limited to specific characteristics and performance criteria.

“The new PUR0200 patent will make it more difficult for potential competitors to develop similar products or to work around our product candidate,” explained Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “The new claims also will make it possible for us to add in a second therapeutic to create a combination product.”

Pulmatrix Inc. (NASDAQ:PULM) is currently developing PUR0200 in Europe and the United States, following regulatory pathways that offer quickest approvals.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) Awarded $860,000 CDC Contract

OpGen Inc. (NASDAQ:OPGN)

Shares of OpGen Inc.(NASDAQ:OPGN) fell 1.4% after the Center for Disease Control and Prevention awarded the company a contract for the development of clinical support tools for antimicrobial stewardship and infection control. The agency has since granted the company $860,000 for the development of a cloud-based mobile software which is to be used in low and middle-income countries.

OpGen Inc. (NASDAQ:OPGN)

CDC Contract Award

OpGen Inc. (NASDAQ:OPGN) is to work with Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc. to bring the solution to fruition. Teqqa is to provide a cloud and mobile based software platform to support antimicrobial stewardship.

The platform is to be used to identify patients that require infection control precautions and assist in the implementations of the necessary precautions. The software will be translated into Spanish to support WHONET data integration.

“OpGen looks forward to working with the CDC to help address this urgent global need,” stated Evan Jones, CEO of OpGen. “Improving antimicrobial stewardship worldwide has been identified by the CDC, the World Health Organization (WHO) and governments worldwide as a core activity in the fight to contain and manage infections from multidrug-resistant pathogens.”

OpGen Inc. (NASDAQ:OPGN) is also developing the Acuitas AMR Gene Panel u5.47, a PCR test designed to detect antibiotic resistance genes. The test can detect up to five bacterial pathogens in clinical isolate and urine specimens. It can also be used to detect up to 47 antimicrobial resistance genes.

According to OpGen’s senior vice president of research and development, Dr. Terry Walker, antimicrobial drug resistance is an urgent global health concern.

“Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development,” said Dr. Walker.

OPGN Stock Performance

The CDC award did little to strengthen investor confidence in the precision medicine company. The stock has underperformed the overall industry, having shed more than 70% in market value since the start of the year.

OpGen Inc. (NASDAQ:OPGN) is currently trading in a downtrend as investors sentiments on the street continue to drop. However, the stock is currently rated as a ‘strong buy’ by two analyst firms according to data compiled by Zacks Investment Research.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

SenesTech Inc (NASDAQ:SNES) Gets Boost from Distribution Agreement

SenesTech Inc (NASDAQ:SNES)

SenesTech Inc (NASDAQ:SNES) stock is up over 75% in the first 1.5 hours of trading after the company announced a national distribution agreement with Univar. The thinly traded pest-control company typically trades less than 100,000 shares per day but one hour into today’s session over 420,000 shares have exchanged hands.

Shares of SenesTech Inc (NASDAQ:SNES)

Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech stated in a press release “Univar is an excellent sales and distribution partner for SenesTech, with their extensive breadth and depth of coverage, their direct connection with the pest control operators, and their commitment to sustainability. They will immediately provide us with nationwide sales coverage and nine dedicated sales representatives. As they have assured us, as our distributor, Univar sees their role as an active partner in creating and building a market for ContraPest.”

ContraPest is a liquid fertility control bait for rodents that targets the reproductive capacity of both male and female rats, rendering them infertile.

SNES Stock Review

Shares of SenesTech Inc (NASDAQ:SNES) recently touched $1.58 which established a new 52-week low. The 52-week high, $10.69, was established in early 2017. SNES shares are down over 80% year-to-date despite having sales that have increased from $200,000 in 2014 to $300,000 in 2016. Per share losses shrunk from (-$1.80) in 2015 to (-$1.08) for 2016. Additionally, the company has managed to keep the number of outstanding shares at the same level (10.13 million) for the last three years, thereby avoiding shareholder dilution that sometimes accompanies companies in rapid growth.

Analysts have given SNES shares a 1-year consensus price target of $14 according to the NASDAQ.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SNES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DURECT Corporation (NASDAQ:DRRX) Sinks on Phase 3 Results

DURECT Corporation (NASDAQ:DRRX)

DURECT Corporation (NASDAQ:DRRX) shares cratered over 60% on Friday on a volume figure of over 8.6 million – DRRX stock previously had an average daily volume of just 456,000. Investors bailed on the biotechnology company after the biotechnology company announced that its drug candidate, Posimir failed to meet its primary efficacy endpoint of pain reduction in a statistical meaningful manner in the Phase 3 PERSIST study. The primary efficacy endpoint was a reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.

DURECT Corporation (NASDAQ:DRRX)

DRXX Share Action

DRRX stock ended Thursday at $1.97. Then, on Friday, DURECT Corporation (NASDAQ:DRRX) shares gapped down to open at $0.84. Throughout the day the stock tried to breech and sustain the $1 level. However DRXX closed at $0.78 – only $0.04 above the 52-week low of $0.74 established back in May. Since that low, the shares had been on a clear uptrend and traded just under $2.20 the two days prior to the crash.

Sandoz Deal

DURECT Corporation (NASDAQ:DRRX) and Sandoz AG (“Sandoz”) entered into a license agreement to develop and market POSIMIR in the United States, and the agreement became effective in June 2017. DURECT retains commercialization rights in the rest of the world. Under terms of the agreement, Sandoz made an upfront payment of $20 million, with the potential for up to an additional $43 million in milestone payments based on successful development and regulatory milestones, and up to an additional $230 million in sales-based milestones. DURECT is responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval. DURECT Corporation (NASDAQ:DRRX) also has certain manufacturing obligations under this agreement.
DURECT Corporation (NASDAQ:DRRX) posted a profit of ($0.16) per share in 2012. Since then, losses have been posted every year and in 2016 they posted their largest loss of (-$0.18) per share. In 2016 the company also their lowest sales figure of 14 million. Currently, two analyst have a “Hold rating on DRXX shares and one has the stock rated at a “Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) Rockets on Open!

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) stock gapped up to open the trading day on news that The Safariland Group announced a newly formed partnership with Digital Ally® for an exclusive distribution agreement of Digital Ally’s VuLink® car based auto-activation system. Twenty minutes into trading, DGLY shares have traded 2.4 million shares versus the listed daily average of just 47,300 – or 500 times the average!

digital ally, DGLY

Stan Ross, CEO of Digital Ally, Inc. (NASDAQ:DGLY) “We are pleased that others are recognizing the importance and value of our products and intellectual properties, especially our patented VuLink auto-activation technology. We are excited to partner with VIEVU to give them the products and technology they need to bring this capability to VIEVU’s customers.”

VuLink System

The Digital Ally VuLink system wirelessly sends a signal to automatically activate the user’s body-worn camera based on various actions with the vehicle, such as a siren being activated, lights being turned on, or a door opening. The VuLink system, when connected to the VIEVU body-worn camera can improve consistency in camera activation by automatically turning on the officer’s camera based on agency-selected vehicle triggers. The automatic activation will significantly reduce situations where body-worn camera footage is not available because an the user forgot to activate the camera.

DGLY Stock Action

Digital Ally, Inc. (NASDAQ:DGLY) stock trade near $6 in February before beginning a long, consistent slide that saw the shares touch their 52-week low of $2.15. Yesterday DLGY shares closed at $2.20 then opened today at $3.05 on the news detailed above. The inter-day high, so far, of $3.50 was hit in the first ten minutes and then the sellers stepped in.

Prior to today’s price action, DGLY shares have been underperforming for investors. They have been down over 47% year-to-date and lost 20% in the past month alone. Despite the poor performance over 2017, two analysts have a “Strong Buy” on DGLY stock with a consensus price target of $8.50.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DGLY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ) Awarded Orphan Drug Designation

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 16% after the clinical stage company announced that the European Medicine Agency had granted its immunotherapy, G100, for non-Hodgkin’s lymphoma Orphan Drug Designation. The EMA designation is normally assigned to products targeting the treatment of rare medical conditions with prevalence of not more than 5 in 10,000 people.

The designation accords Immune Design Corp (NASDAQ:IMDZ) a string of benefits not limited to reduced fees for regulatory activities. The company also stands to enjoy protocol assistance when it comes to clinical trials. In addition, the clinical stage immunotherapy company will be granted 10 years of market exclusivity upon approval by regulators in the Union.

The company’s lead drug for the treatment of non-Hodgkin’s lymphoma has also been granted Orphan Drug Designation in the U.S by the Food and Drug Administration. Developed from Immune Design Corp (NASDAQ:IMDZ)’s GLAAS discovery platform, the candidate product is designed to activate innate and adaptive immunity in the tumor microenvironment.

IMDZ Stock Performance

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) free fall in the market shows no signs of slowing down as the stock has shed more than 40% in market value since the start of the month. The stock is currently trading at levels last seen at the start of the year.

Declining investor’s sentiments on the stock follows reports that the company plans to initiate a Phase 3 study of cancer vaccine candidate CMB305 in NY-ESO-1. The timing of the study, slated for mid-2018, appears to have spooked investors. The stock has also been downgraded by analysts at Wells Fargo to a ‘Neutral’ – seen as another cause for alarm among investors.

Immune Design Pipeline

CMB305 is one of Immune Design primary candidates currently in multiple clinical trials in patients with soft tissue sarcoma. The product is being investigated as a monotherapy and in combination with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s RHHBY Tecentriq.

“The trial will have progression-free survival (PFS) followed by overall survival (OS) as co-primary endpoints. If the PFS endpoint is successful, the FDA offered that it may support full approval of CMB305. Depending on the rate of events, final PFS analysis may occur as early as 24 months from the first patient dosed,” Immune Design in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Alcobra Ltd (NASDAQ:ADHD) Makes Strong Move Up

Alcobra Ltd (NASDAQ:ADHD)

Israeli-based Alcobra Ltd (NASDAQ:ADHD) stock gained almost 19% after it was announced that the biotechnology company had entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). Volume exploded and was almost 100 times the daily average by the end of trading.

NASDAQ:ADHD

Deal Details

An Alcobra subsidiary, Arcturus, and Janssen will collaborate to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform. The agreement also includes an option to expand into other infectious and respiratory diseases. Terms of the agreement include Arcturus receiving an upfront cash payment, R&D support, and pre-clinical, development, and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.

Joseph Payne, President and CEO of Arcturus. “Arcturus’ expertise and intellectual property in the field of RNA medicines is complemented by Janssen’s broad capabilities in clinical development, regulatory affairs, and marketing. Together we aim to bring new treatments to patients who are suffering from Hepatitis B and potentially other infectious diseases.”

ADHD Stock Performance

Shares of Alcobra Ltd (NASDAQ:ADHD) are down over 36% for the year but are up almost 40% over the past month. In January ADHD stock plummeted over 50% when it was revealed that several law firms were pursuing class-action status for lawsuits over claims that corporate officers may have violated federal securities laws.

Interestingly, Alcobra Ltd (NASDAQ:ADHD) lists cash per share at $1.55 – more than today’s closing value.

Three firms follow Alcobra Ltd (NASDAQ:ADHD). One rates ADHD shares at a “Strong Buy”. one at a “Hold”, and one at a “Sell”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ADHD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Dextera Surgical Inc (NASDAQ:DXTR)

Bad Day for Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR) gapped down to open trading this morning, then struggled through the rest of the day, and ended down almost 25%. The company released no news that would account for the large move down. The NASDAQ market started lower today as well but ended down just 0.37%. Given that DXTR stock carries a -1.17 Beta, the shares clearly were more volatile than one would expect.

Dextera Surgical Inc (NASDAQ:DXTR)

About Dextera Surgical

Redwood City, CA-based Dextera Surgical Inc (NASDAQ:DXTR) is a global medical device company that develops proprietary stapling devices for minimally invasive surgical procedures. It primarily develops and commercializes MicroCutter 5/80, a cartridge-based micro cutter device used by for thoracic, pediatric, bariatric, colorectal, and general surgeons. The company also designs, manufactures, and markets automated anastomotic systems under the Cardica brand name for use by cardiac surgeons to perform coronary bypass surgery.

DXTR Stock

The medical device company has a market capitalization under $10 million. At the end of 2016, shares of Dextera Surgical Inc (NASDAQ:DXTR) bounced off the critical $1 per share level for three weeks before shooting above $2.25. A long slide in DXTR stock value then began in February of 2017 and shares broke through the psychologically important level of $0.50 in May. Since then DXTR stock has traded in a $0.15 – $0.40 range. Then, this week, DXTR stock hit their 52-week low of $0.13. 2017 has been tough for Dextera Surgical shareholders as DXTR shares have lost over 80% since January.

The company has an uncertain future and observers of the sector believe a sale or merger may be in the best interests of the company and shareholders. Existing shareholders are on the alert for another round of dilution as the company reportedly has just $0.05 in cash per share – that is a short runway, even for a nano-cap company. However, it should be noted that the company has been able to shrink its losses each year. In 2013, the per share loss was (-$3.95). Each year since then has seen a smaller loss and, for FY2017, the loss was a smaller (-$1.72). Also benefitting shareholders is the low share price which reflects a short-sale position on the stock’s float of less than 10%. Curiously, two investment firms rate DXTR stock as a “Strong Buy” and one rates the shares a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) shares gained 9.9% after the biotechnology company reported positive preclinical research, demonstrating synergy of PCM-075 in combination with Johnson & Johnson (NYSE:JNJ) drug Zytiga. Trial results indicate that when combined, the two appear to signal a previously unknown pathway.

TrovaGene Inc. (NASDAQ:TROV)

According To Trovagene Chief Scientific Officer, Mark Erlander, the unique combination could enhance the PCM-075 mechanism in arresting cells during mitosis with subsequent tumor cell death. The biotechnology company is investigating the adenosine triphosphate (ATP) competitive inhibitor for the treatment of metastatic castration-resistant prostate cancer.

“We previously completed a Phase 1 trial in metastatic solid tumor cancers, which provided a recommended Phase 2 dose and dosing schedule for PCM-075 in a combination regimen. We are working closely with key investigators to develop a Phase 2 clinical trial protocol with oral dosing of PCM-075 and abiraterone utilizing our existing solid tumor IND,” said CEO, Bill Welch.

Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has already granted an Orphan Drug Designation to PCM-075 for the treatment of acute myeloid leukemia. According to TrovaGene Inc. (NASDAQ:TROV) CEO, the designation underscores the agency desire to accelerate the development of the therapy given that AML affects nearly 20,000 people every year in the U.S.

The Orphan Drug Designation will allow TrovaGene to accelerate the development of PCM-075. The designation also allows the company up to seven years of market exclusivity upon regulatory approval. The company plans to initiate a Phase 1b/2 open-label trial to evaluate the safety and anti-leukemic activity of the candidate drug in combination with standard care.

TROV Stock Performance

TrovaGene Inc. (NASDAQ:TROV) has been a shadow of itself in the market this year as the stock is down by more than 50% as it continues to trade in a strong downtrend. Investor confidence on the tock appears to have hit all-time lows, seen by the stock struggling to rise above the $1 a share mark.

The company reported a net loss of (-$36.81) million in its most recent quarter as it continues to waver on its path to profitability. Arousing further investors’ concerns is the rate at which the company is burning cash. TrovaGene Inc. (NASDAQ:TROV) reportedly has $7.78 million in the bank compared to negative cash flows of $29.40 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TROV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Viking Therapeutics Inc (NASDAQ:VKTX)

Fireworks Continue for Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX) shares continued their strong upward trajectory today as the biotechnology firm’s stock rose over 25% in today’s trading to end the day at $2.60. Volume was heavy, almost ten times their normal daily average. The gains came in two waves, one right from the moment the market opened, and another buying wave began one hour before the market close.

A 2-day chart:

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Recent Developments

Viking Therapeutics Inc (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. On October 4, 2017 VKTX shares jumped almost 9% when the company announced positive top-line results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal metabolic disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. X-ALD is estimated to occur in approximately 1 in 17,000 births. The results showed that 25 weeks of treatment with VK0214 led to robust effects on multiple very long chain fatty acids.

VKTX Stock

Performance for shares of Viking Therapeutics Inc (NASDAQ:VKTX) has been strong despite the lack of any sales – though that is not unusual for a clinical-stage biotechnology firm. Over the past year shares have risen over 126% and are up 134% for the past quarter. Today’s spike eclipsed the previous 52-week high of $2.44. In 2015 the company posted a per share loss of (-$3.68) but that shrank to a per share loss of (-$0.91) in 2016. However it should be noted that in 2016 the company diluted shareholder value. In 2015 there were 6.36 million shares outstanding and then in 2016 that number grew to 16.28 million.

Viking Therapeutics Inc (NASDAQ:VKTX) is covered by two analysts. Both rate VKTX shares as a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.